Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Corolabs
Corolabs Overview
Corolabs develops a combination of inhaled medications together with a novel delivery system capable of reaching the deep lung.
The company’s aerosol technology is used to produce and deliver sub-micron droplets to the alveoli of the lung, enabling localized treatment of lower respiratory diseases as well as systemic drug delivery. This novel technology allows home-based treatments of lower respiratory diseases, traditionally treated only in hospital settings by intramuscular injection or intravenous therapy.
Additional advantages of targeted drug delivery to the deep lung include potential rapid onset of action as well as the opportunity for dose sparing and reduced side effects of systemically available drugs.
Corolabs was established shortly after the onset of the COVID-19 outbreak in Israel, after it became evident that COVID-19 mortality occurs as a result of deep-lung infections triggered by the coronavirus.